Avid Bioservices Inc (CDMO)

[north40000]

GILD just turned + today. New PT by Jeffries of $80. In addition to BMY, think of AZN as a GILD target, depending on results from 1) its P3 Mystic trial(expected this month or quarter), and/or 2) Durvo trials(that mab potentially brings PPHM into play).

Entertain yourselves, OT, by looking at posts of Sam on Amarin IHub board this morning. Those All Time High scrips for its anti-inflammatory EPA omega-3 fatty acid, Vascepa, are mostly off-label(current FDA approval is for a very narrow CVD indication). AMRN's Reduce-It P3 trial will have a 2nd interim look/recommendation
any time. Both GILD and AZN will be looking there too(besides MRK or PFE). I do not know whether Dr. Wolchok has followed up on my suggestion in December at Wistar to administer EPA as an anti-inflammatory therapy prior to initiating I-O therapy.